Differences in the patterns and outcomes of enhanced viral replication between hepatitis C virus and hepatitis B virus in patients with hepatocellular carcinoma during transarterial chemolipiodolization

다국어 초록 (Multilingual Abstract)

Background/Aims: Enhanced replication of hepatitis C virus (HCV) is well described in the setting of moderate to severe immunosuppression. The aims of this retrospective study were to determine the incidence of enhanced HCV replication in hepatocellular carcinoma (HCC) patients undergoing transarterial chemolipiodolization (TACL) and to identify the factors associated with enhanced replication of HCV. The clinical pattern of enhanced HCV replication was compared with hepatitis B virus (HBV) reactivation during TACL. Methods: This study enrolled 49 anti-HCV-seropositive patients who were diagnosed with HCC between January 2005 and December 2010 and who underwent TACL using epirubicin and/or cisplatin with consecutive HCV RNA copies checked. For comparison, 46 hepatitis B surface antigen1-positive patients with HCC who were treated with TACL were also enrolled. The frequency, associated factors, and clinical outcomes of enhanced HCV replication were analyzed and compared with those of HBV reactivation during TACL. Results: Enhanced replication of HCV occurred in 13 (26.5%) of the 49 anti-HCV-seropositive patients during TACL. Of these 13 patients, 4developed hepatitis, but none of the subjects developed decompensation due to the hepatitis. No significant clinical factors for enhanced HCV replication during TACL were found. Compared with HBV reactivation, the frequency of hepatitis attributed to enhanced HCV replication was significantly lower than that for HBV reactivation (8.2% vs. 23.9%,P=0.036). Conclusions: TACL can enhance HCV replication; however, the likelihood of hepatitis and decompensation stemming from enhanced HCV replication was lower than that for HBV reactivation in patients undergoing TACL.

참고문헌 (Reference)

1 Yeo W, "virus reactivation during chemotherapy in breast cancer patients" 88 : 209-215, 2004

2 Urbani S, "Virus-specific CD8+ lymphocytes share the same effector-memory phenotype but exhibit functional differences in acute hepatitis B and C" 76 : 12423-12434, 2002

3 Jang JW, "Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma" 41 : 427-435, 2004

4 Farci P, "The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies" 288 : 339-344, 2000

5 Afdhal NH, "The natural history of hepatitis C" 24 (24): 3-8, 2004

6 Usuda S, "Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product" 80 : 97-112, 1999

7 Gerlach JT, "Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C" 117 : 933-941, 1999

8 Lok AS, "Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study" 100 : 182-188, 1991

9 Lo CM, "Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma" 35 : 1164-1171, 2002

10 Brown DB, "Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy" 17 : 225-232, 2006

11 Bruix J, "Prognostic assessment and evaluation of the benefits of treatment" 35 (35): 138-142, 2002

12 Radkowski M, "Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C" 41 : 106-114, 2005

13 Bowen DG, "Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man" 201 : 1709-1714, 2005

14 Shoukry NH, "Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection" 197 : 1645-1655, 2003

15 Firpi RJ, "Management of viral hepatitis in hematologic malignancies" 22 : 117-126, 2008

16 Zuckerman E, "Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies" 83 : 1224-1230, 1998

17 Li YH, "Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma" 106 : 1320-1325, 2006

18 Idilman R, "Lamivudine prophylaxis in HBV carriers with haematooncological malignancies who receive chemotherapy" 55 : 828-831, 2005

19 Nascimbeni M, "Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees" 77 : 4781-4793, 2003

20 Pham TN, "Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C" 78 : 5867-5874, 2004

21 Rumi MG, "Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients" 54 : 402-406, 2005

22 Dai MS, "Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration" 24 : 540-546, 2004

23 Xunrong L, "Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy-pathogenesis and management" 11 : 287-299, 2001

24 Pitini V, "HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy" 150 : 116-118, 2010

25 Vento S, "Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus" 347 : 92-93, 1996

26 Yeo W, "Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors" 62 : 299-307, 2000

27 Melichar B, "Effect of irinotecan on the phenotype of peripheral blood leukocyte populations in patients with metastatic colorectal cancer" 49 : 967-970, 2002

28 Lau GK, "Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy" 125 : 1742-1749, 2003

29 Thimme R, "Determinants of viral clearance and persistence during acute hepatitis C virus infection" 194 : 1395-1406, 2001

30 Llovet JM, "Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial" 359 : 1734-1739, 2002

31 Lechner F, "Analysis of successful immune responses in persons infected with hepatitis C virus" 191 : 1499-1512, 2000

32 Yoshikawa M, "A randomized trial of intrahepatic arterial infusion of 4'-epidoxorubicin with Lipiodol versus 4'-epidoxorubicin alone in the treatment of hepatocellular carcinoma" 33 : 149-152, 1994

33 Jang JW, "A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization" JOHN WILEY & SONS INC 43 : 233-240, 200602